Table II.

Associations of PFS with FAR and other clinicopathological factors.

	Univariate analysis			Multivariate analysis
Factor	HR	95% CI	P-value	HR	95% CI	P-value
Age >60 years	0.988	0.778–1.255	0.921
Male sex	1.140	0.884–1.471	0.313
Body mass index
<18.5 or >25 kg/m2	0.940	0.717–1.231	0.651
ECOG PS score >1	1.295	0.940–1.784	0.114	1.164	0.832–1.629	0.376
Histological differentiation, poor/mucinous	1.144	0.873–1.500	0.329
Metastasis in >1 organ	1.464	1.138–1.883	0.003	1.232	0.920–1.651	0.162
Peritoneal metastasis	1.813	1.388–2.367	<0.001	1.370	1.011–1.857	0.042
TNM stage IV	1.412	1.042–1.913	0.026	1.060	0.759–1.481	0.731
CEA >5 ng/ml	1.162	0.913–1.480	0.223
CA19-9 >37 U/ml	0.972	0.761–1.243	0.823
CA72-4 >6 U/ml	1.506	1.178–1.926	0.001	1.375	1.068–1.770	0.013
Hemoglobin <115 g/l	0.919	0.718–1.176	0.502
Fibrinogen <3.8 g/l	0.567	0.441–0.729	<0.001	0.805	0.564–1.149	0.231
Albumin ≥40.55 g/l	0.697	0.547–0.887	0.003	0.770	0.595–0.998	0.048
FAR ≤10.03	0.468	0.360–0.608	<0.001	0.638	0.436–0.932	0.020

FAR, fibrinogen-to-albumin ratio; PFS, progression-free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.